INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,736,752 | -20.4% | 848,800 | -52.5% | 0.37% | -13.6% |
| Q2 2023 | $19,780,312 | +12596.9% | 1,788,455 | +15317.7% | 0.43% | +14333.3% |
| Q1 2023 | $155,788 | +8.6% | 11,600 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $143,492 | -97.9% | 11,600 | -97.7% | 0.00% | -98.3% |
| Q3 2022 | $6,956,000 | +725.1% | 498,600 | +716.3% | 0.17% | +690.9% |
| Q2 2022 | $843,000 | -87.2% | 61,079 | -84.9% | 0.02% | -85.8% |
| Q4 2021 | $6,606,000 | +415.3% | 405,494 | +369.9% | 0.16% | +342.9% |
| Q3 2021 | $1,282,000 | -51.3% | 86,300 | +321.0% | 0.04% | -96.5% |
| Q1 2016 | $2,634,000 | – | 20,500 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |